Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Prospective Evaluation of LDL Levels in Patients Converted From Zetia (Ezetimibe)10 mg to 5 mg

The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.

Inclusion Criteria:

• Subjects receiving ezetimibe 10 mg

• Subjects who have demonstrated compliance with ezetimibe as evidenced by the following Proportions of Days Covered patterns (which represent a PDC of more than 75%):

  • 90 day prescriptions: Filled a ezetimibe prescription within the previous 4 months
  • 60 day prescriptions: Filled a ezetimibe prescription within the previous 2.5 months
  • 30 day prescriptions: Filled a ezetimibe prescription within the previous 1.5 months

• Patients willing and able to provide signed informed consent

Exclusion Criteria:

• Patients not receiving ezetimibe
• Patients receiving ezetimibe 5 milligrams
• Patients with a history of being titrated from ezetimibe 5 to 10 mg. Stroke,TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within the 3 months
• Cancer undergoing active treatment
• Participation in any clinical study within the last 30 days
• Drug addiction or alcohol abuse within the past 6 months
• Patients unwilling or unable to provide informed consent
• Patients with poor compliance
• Women of childbearing potential